Chemo-potentiation was seen when NAMPT inhibitors were combined with agents that cause DNA damage, such as 5-fluorouracil (5-FU) in gastric cancer [71], fludarabine and cytarabine in leukemia [135,154], cisplatin or etoposide in neuroblastoma [138], temozolomide in gliomas [149,150], gemcitabine, paclitaxel and etoposide in pancreatic cancer cells [144,145], pemetrexed in NSCLC [143], and bendamustine and melphalan in Waldenstrom macroglobulinemia (WM) [159]. Here, NAMPT is linked to Waldenstrom macroglobulinemia.